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Abstract
Background: Chemoresistance is one of the main obstacles to successful cancer therapy and is
frequently associated with Multidrug resistance (MDR). Many different mechanisms have been
suggested to explain the development of an MDR phenotype in cancer cells. One of the most
studied mechanisms is the overexpression of P-glycoprotein (P-gp), which is a product of the MDR1
gene. Tumor cells often acquire the drug-resistance phenotype due to upregulation of the MDR1
gene. Overexpression of MDR1 gene has often been reported in primary gastric adenocarcinoma.
Methods: This study investigated the role of p38-MAPK signal pathway in vincristine-resistant
SGC7901/VCR cells. P-gp and MDR1 RNA were detected by Western blot analysis and RT-PCR
amplification. Mitgen-activated protein kinases and function of P-gp were demonstrated by
Western blot and FACS Aria cytometer analysis. Ap-1 activity and cell apoptosis were detected by
Dual-Luciferase Reporter Assay and annexin V-PI dual staining.
Results: The vincristine-resistant SGC7901/VCR cells with increased expression of the multidrug-
resistance 1 (MDR1) gene were resistant to P-gp-related drug and P-gp-unrelated drugs.
Constitutive increases of phosphorylated p38-MAPK and AP-1 activities were also found in the
drug-resistant cells. Inhibition of p38-MAPK by SB202190 reduced activator protein-1 (AP-1)
activity and MDR1  expression levels and increased the sensitivity of SGC7901/VCR cells to
chemotherapy.
Conclusion: Activation of the p38-MAPK pathway might be responsible for the modulation of P-
glycoprotein-mediated and P-glycoprotein-unmediated multidrug resistance in the SGC7901/VCR
cell line.
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Background
Multidrug resistance (MDR) is a serious problem in chem-
otherapy and is one of the main causes of poor outcome
following cancer treatment. The MDR phenotype is often
related to overexpression of drug-efflux pumps in cancer
cells. P-glycoprotein (P-gp), a 170-kDa transmembrane
glycoprotein encoded by the MDR1 gene, is one of the
best characterized drug efflux pumps [1-3]. Overexpres-
sion of P-gp on the surface of tumor cells allows removal
of cytotoxic drugs out of the cell in an energy-dependent
manner, thereby reducing drug accumulation and increas-
ing multidrug resistance. In addition, inhibition of the P-
gp function or inhibition of its expression could prevent
the P-gp-mediated MDR phenotype and improve the
effectiveness of chemotherapy[4]. However, there is accu-
mulating evidence that P-gp-associated MDR cells
develop other pathways instigating chemoresistance to P-
gp-unrelated drugs such as cisplatin and 5-FU [5-9].
Expression of P-gp has been reported to be regulated
through transcriptional and post-transcriptional mecha-
nisms and by various endogenous and environmental
stimuli that evoke stress responses [10]. The transcrip-
tional factor AP-1 has been shown to mediate P-gp expres-
sion [11]. Regulation of the AP-1 pathway is highly
complex and activation of certain signal pathways seems
to stimulate the transcriptional activity of AP-1 [12].
Simultaneous expression of P-gp and activation of several
signal pathways has been found in some cancer cells.
Moreover, these pathways have been reported to regulate
the expression of P-gp in some multidrug-resistant cell
lines [13-15], and blocking these pathways with their spe-
cific inhibitors has also been found to reduce P-gp expres-
sion [13,16]. These studies suggest that signal pathways
play a positive role in the regulation of P-gp expression
In the present study, we assessed p38-MAPK phosphoryla-
tion and AP-1 activity in drug-resistant and drug-sensitive
gastric cancer cells. Furthermore, the effect of the p38-
MAPK inhibitor SB202190 on the MDR1 gene expression
and AP-1 activity was also tested.
Methods
Cell Culture and reagents
Drug-sensitive human gastric cancer cell SGC7901 and
the corresponding vincristine-resistant cell SGC7901/VCR
were kindly provided by the Institute of Digestive Diseases
(Fourth Military Medical University). All cells were culti-
vated in RPMI1640 medium (Gibco) supplemented with
10% heat-inactivated fetal calf serum in a CO2 incubator.
To maintain the drug-resistance phenotype of SGC7901/
VCR cells, vincristine (1.0 μg/ml) was also added to the
medium. Cisplatin, 5-fluorouracil (5-FU) and epirubicin
were purchased from QILU PHARMA (JiNan, Shandong,
China). SB202190 was obtained from TOCRIS (Ballwin,
MO, USA). The AP-1 luciferase report plasmid and the
dominant-negative mutant p38 (DN-p38) plasmid were
kind gifts from Dr Chuanshu Huang [17,18].
Cell Viability Assay
A total of 4,000 SGC7901/VCR and SGC7901 cells were
seeded in a 96-well plate. After 24 hours, cells were treated
with different concentrations of 5-FU, cisplatin, or epiru-
bicin. After 72 hours, the MTT assay was performed to
evaluate cell viability.
Luciferase assay
Cells were cultured in a twenty four-well plate until they
reached 85–90% confluence. In all, total 0.8–1 μg plas-
mid DNA (DN-p38 plasmid mixed with AP-1 luciferase
report plasmid) and 2.5 μl LipofectAMINE 2000 (Invitro-
gen, Carlsbad, CA, USA) mixed together were used to
transfect each well in the absence of serum. After 4–6 h,
the medium was replaced with 10% fetal calf serum
RPMI1640. Approximately 36 h after the beginning of the
transfection, cells were lysed and Luciferase assays were
performed using the Dual Luciferase Reporter Assay Sys-
tem (Promega, WI, USA). A Renilla luciferase plasmid was
also cotransfected in each experiment as an internal con-
trol for transfection efficiency. The relative luciferase activ-
ity reported here is the mean of three replicate
experiments.
RT-PCR Amplification
RNA was extracted from cells using Trizol (Invitrogen,
Carlsbad, CA, USA). cDNA was synthesized using MMLV
reverse transcriptase(Promega, WI, USA) and 2 μg total
RNA and oligo dT18-primers. Two-microliter aliquots of
cDNA were used for PCR amplification and primers were
as follows: sense 5'-AAGCTTAGTACCAAAGAGGCTCTG-
3' and antisense 5'-GGCTAGAAACAATAGTGAAAACAA-3'
for MDR-1 [19]; sense 5'-TGACGGGGTCACCCACACT-
GTGCCCATCTA-3' and antisense 5'-CTAGAAGCATT-
GCGGTGGACGATGGAGGG-3') for β-actin [20]. PCR
used 32 cycles of 30 seconds at 94°C, 45 seconds at 58°C,
and 30 seconds at 72°C for MDR1 and β-actin. PCR prod-
ucts were separated by 2% agarose gel electrophoresis,
and bands were visualized under ultraviolet (UV) radia-
tion after staining with ethidium bromide. Gels were pho-
tographed and bands were analyzed by computerized
densitometry.
Western-blot analysis
Protein extracts were prepared using a nuclear extract kit
(Active Motif, Carlsbad, CA, USA). Protein samples (30
μg) were separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) and transferred to nitrocellulose mem-
branes. Membranes were incubated at 4°C overnight with
various primary antibodies against P-gp (Sigma, St Louis,
MO, USA), β-actin, and phosphorylated or non-phospho-BMC Cancer 2008, 8:375 http://www.biomedcentral.com/1471-2407/8/375
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rylated extracellular kinase receptor kinases (ERKs), Jun
N-terminal kinases (JNKs) and p38 kinase (Cell Signaling
Technology, Beverly, MA, USA). The resulting immunob-
lots were visualized with horseradish peroxidase-coupled
goat anti-rabbit or anti-mouse immunoglobulin using an
enhanced chemiluminescence (ECL) substrate system
(Amersham Biosciences, Piscataway, NJ, USA).
Apoptosis analysis with annexin V-PI dual staining
Cells (2 × 105 per well) were cultured in six-well plates to
70%–80% confluence. Cells were then treated with the
indicated concentrations of chemotherapeutic agents,
with or without SB202190 (10 μM), for 24 hours. Cells
were collected and the annexin V-PI dual-staining assay
was performed according to the manufacturer's instruc-
tions ((Nanjing Keygen Biotech, China). Collected cells
were briefly washed with ice-cold phosphate-buffered
saline (PBS) twice and resuspended in 300 μl 1 × binding
buffer containing 5 μl Annexin V and 5 μl Propidium
iodide (PI) for 30 minutes at room temperature in the
dark. After incubation; the cells were analyzed using a
FACS Aria cytometer (Becton Dickinson; San Jose, CA).
FACS analysis for MAP-kinase
Cells were collected and resuspended in 0.5–1 ml PBS and
formaldehyde was added to a final concentration of 2–
4%. The cells were fixed for 10 minutes at 37°C and then
chilled on ice for 1 minute. For permeabilization, pre-
chilled cells were centrifuged and resuspended in 90% ice-
cold methanol. Cells were then incubated for 30 minutes
on ice. Permeabilized cells (1 × 106) were mixed with 100
μl 0.5% bovine serum albumin (BSA)/PBS containing 2
μg/ml phospho-ERK, phospho-p38 MAPK, or phospho-
JNK-specific antibody and incubated for 1 hour at room
temperature. Cells were then washed with 0.1% BSA/PBS
followed by incubation with goat anti-mouse immu-
noglobulin G (IgG) fluorescein isothiocyanate (FITC)-
conjugated antibodies (50 μg/ml, KPL) for 30 minutes at
room temperature. Cells were washed again with 0.1%
BSA/PBS, then resuspended in 0.5 ml PBS and analyzed
by flow cytometry.
Accumulation and efflux of Rh123 was measured by flow 
cytometry
The measurement of Rh123 accumulation was performed.
Briefly, cells (5 × 105 per sample) were incubated with 1
μg/mL of Rh123 in the dark at 37°C in 5% CO2 for 120
min. SB202190 was added to cultures at the same time as
Rh123. Following Rh123 accumulation, cells were
washed twice with ice-cold Hanks' Balanced Salt (HBSS)
(without phenol red), placed in HBSS with 10% fetal
bovine serum on ice. The green fluorescence of Rh123 was
measured by flow cytometry. For determination of Rh123
efflux, cells were loaded for 120 min with Rh123 in the
absence of SB202190, and then the medium was replaced
with Rh123-free medium containing SB202190, or the
vehicle. Following efflux intervals of 60 min, the medium
was removed, and the cells were washed twice with ice-
cold HBSS and prepared for flow cytometry as described
earlier.
Statistical analysis
Values were expressed as means ± standard deviation
(S.D.). Differences were analyzed using the Student's t-
test. A P-value of < 0.05 was considered significant.
Results
SGC7901/VCR cells are more resistant to chemotherapy 
than SGC7901 cells
The human gastric cancer cell line-SGC7901/VCR is a vin-
cristine-resistant cell line that is derived from the vincris-
tine-sensitive parent cell line SGC7901 [21]. To test
whether SGC7901/VCR is more resistant to other chemo-
therapeutic agents than SGC7901, we treated these two
kinds of cells with different concentrations of cisplatin, 5-
FU and epirubicin. MTT assay results and IC50 values
showed that SGC7901/VCR cells were more resistant to
these chemotherapeutic agents. (Fig. 1A–C, Table 1 [see
Additional file 1]). These results also indicated that
SGC7901/VCR is a multidrug-resistant cancer cell line,
which is resistant to P-gp-related drugs (vincristine and
epirubicin) and P-gp-unrelated drugs (cisplatin and 5-
FU).
Increased expression of MDR1 in SGC7901/VCR cells
Although many different mechanisms have been sug-
gested to explain the development of an MDR phenotype
in cancer cells, one of the most extensively studied form of
MDR is the P-gp-associated MDR phenotype, and a
number of studies have convincingly supported that P-gp
expression in tumor cells correlates with poor prognosis
of chemotherapy [22]. Meanwhile, vincristine and epiru-
bicin are known as P-glycoprotein substrate and cells
resistant to these two drugs often overexpress P-glycopro-
tein. Therefore, we used Western-blot and RT-PCR analy-
ses to investigate MDR1 gene expression in SGC7901 and
SGC7901/VCR cells. As shown in Fig. 1D and 1E,
SGC7901/VCR cells have increased expression levels of P-
gp protein and MDR1 mRNA than SGC7901. Further-
more, we investigated whether cisplatin or 5-FU could
induce MDR1 gene expression in SGC7901 cells; RT-PCR
analyses showed that cisplatin or 5-FU treatment could
not induce MDR1  gene mRNA expression (data not
show). Thus, these results suggested P-gp-related or unre-
lated mechanism may involved in SGC7901/VCR cells to
develop chemoresistance.
Activation of p38-MAPK/AP-1 pathway in SGC7901/VCR 
cells
Several studies have suggested that expression of MDR1 is
regulated at the transcriptional level by multiple factors
that can be activated via the stress-response pathways [23-BMC Cancer 2008, 8:375 http://www.biomedcentral.com/1471-2407/8/375
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26]. AP-1 is a well-known mediator of the stress-response
pathways, which are composed of heterodimers from the
Jun and Fos protein families [27]. Previous report has
demonstrated that AP-1 is a transcription factor of MDR1
[11]. We therefore investigated AP-1 activities in SGC7901
and SGC7901/VCR cells using a luciferase reporter assay.
Our results clearly showed that AP-1 activity was much
greater in SGC7901/VCR cells than in SGC7901 cells (Fig.
2A).
AP-1 is a downstream target of the mitogen-activated pro-
tein (MAP) kinase pathway [27], and significant changes
of MAP kinase levels in some drug-resistant cells have
been reported [28,29]. We investigated the signaling path-
way that regulates the activation of AP-1 in SGC7901/VCR
and SGC7901 cells. Western-blot analysis of MAP kinases
revealed that phosphorylation of p38-MAPK, but not
ERKs and JNKs, is specifically increased in SGC7901/VCR
cells (Fig. 2B). These results were confirmed by FACS anal-
ysis: SGC7901/VCR cells showed significant increased
phosphorylation of p38-MAPK (Fig. 2C). Luciferase assay
results also showed that inhibition of p38-MAPK by
SB202190 or after transfection with the DN-p38 plasmid
significantly reduced AP-1 activity in SGC7901/VCR cells
(Fig. 2D, E). Furthermore, incubation with cisplatin for 24
SGC7901/VCR cells that overexpress MDR1 are more resist- ant to chemotherapy than SGC7901 cells Figure 1
SGC7901/VCR cells that overexpress MDR1 are 
more resistant to chemotherapy than SGC7901 cells. 
(A-C) After treatment with different concentrations of 5-FU, 
cisplatin or epirubicin for 72 hours, cell viability was deter-
mined using the MTT assay. The viability of the untreated 
cells was taken as 100%. Points, mean of three independent 
experiments; bars, SD. Significant differences are indicated by 
asterisks. *, P < 0.05. (D) SGC7901/VCR and SGC7901 cells 
were harvested to prepare cell lysates. The lysates were sub-
jected to SDS-PAGE and blotted with anti-P-gp antibody. (E) 
RT-PCR assays were performed to detect MDR1 mRNA. A 
representative example of an experiment that was repeated 
three times is shown.
Activation of p38 MAPK/AP-1 pathway in SGC7901/VCR  cells Figure 2
Activation of p38 MAPK/AP-1 pathway in SGC7901/
VCR cells. (A) SGC7901/VCR and SGC7901 cells were 
transfected with AP-1 luciferase reporter plasmids. After 24 
hours, the cells were collected and luciferase assays were 
performed. The luciferase activity results in SGC7901 cells 
were normalized to 1.0. Error bars indicate standard devia-
tions. The values shown represent the means of at least 
three separate experiments. Significant differences are indi-
cated by asterisks. *, P < 0.05. (B) Levels of phosphorylated 
and non-phosphroylated MAP kinases (p38-MAPK, ERKs and 
JNKs) in SGC7901/VCR and SGC7901 cells were detected 
using Western-blot analyses. A representative example of an 
experiment that was repeated three times is shown. (C) 
FACS analysis of p38-MAPK, ERK and JNK phosphorylation. 
A representative example of an experiment that was 
repeated three times is shown. (D-E) Analysis of AP-1 activ-
ity using the luciferase assay in SGC7901/VCR cells treated 
or untreated with SB202190 (10 μM), or cotransfected with 
the DN-p38 plasmid for 24 hours. The luciferase activity in 
control samples was normalized to 1.0. Error bars indicate 
standard deviations. The values shown represent the means 
of at least three separate experiments. Significant differences 
are indicated by asterisks. *, P < 0.05. (F) SGC7901 cells 
were incubated with cisplatin (2 μg/ml) for 24 h, and then 
cells were collected. FACS analysis was used to detect p38-
MAPK phosphorylation.BMC Cancer 2008, 8:375 http://www.biomedcentral.com/1471-2407/8/375
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h can also induce p38 phosphorylation in SGC7901 cell s
(Fig. 2F). Taken together, these results showed that the
p38-MAPK/AP-1 pathway was activated in SGC7901/VCR
cells, and contributed to chemoresistance.
Inhibition of p38-MAPK increases sensitivity of SGC7901/
VCR cells to chemotherapy
Our previous data clearly showed that the p38-MAPK/AP-
1 pathway was activated in SGC7901/VCR cells. Moreo-
ver, AP-1 was reported to be involved in MDR1 upregula-
tion [11]. We then investigated the effects of p38-MAPK
inhibition on MDR1  expression and function of P-gp.
Western-blot analysis showed that inhibition of p38-
MAPK by SB202190 markedly downregulated P-gp
expression in SGC7901/VCR cells. This effect was con-
firmed by RT-PCR analysis (Fig. 3A–C). To examine the
effect of SB202190 on function of P-gp, Rh123 accumula-
tion and efflux studies were chosen. As shown in Figure
3D, Rh123 accumulation and retention in SGC7901/VCR
cells were obviously less than that in SGC7901 cells. After
treatment with SB202190 (10 μM), Rh123 accumulation
and retention in SGC7901/VCR cells were increased; how-
ever, there was no change in SGC7901 cells(Fig. 3D).
Thus, our results clearly showed that inhibition of p38-
MAPK reduced MDR1 gene expression and function of P-
gp in SGC7901/VCR cells.
Upregulation of the MDR1 gene has been reported to be
closely related to chemotherapy resistance, and inhibition
of the MDR1 gene has been shown to increase the sensi-
tivity of tumor cells to P-gp-related chemotherapeutic
agents [30]. Although cisplatin and 5-FU are not the sub-
strates of P-gp, it has been reported that increased expres-
sion of c-jun contributed to cisplatin resistance,
meanwhile it was also reported that 5-FU can induce c-jun
phosphorylation and activate both AP-1-specific tran-
scription and DNA binding [31,32]. We therefore tested
whether inhibition of p38-MAPK could restore the chem-
otherapeutic sensitivity of drug-resistant tumor cells to P-
gp-related drug and P-gp-unrelated drugs. SGC7901/VCR
cells were treated with 5-FU, cisplatin and eprubicin for 24
hours, with or without 2-hour pretreatment with
SB202190 (10 μM). The morphology of cells was
observed, and photographs were taken under the micro-
scope. Annexin-V/PI staining analysis was performed to
detect cell apoptosis. As shown in Fig. 4A, cells treated
with SB202190, but not control cells (not treated with
SB202190), showed significantly increased levels of cell
death and exhibited typical morphologic features of apop-
totic cell death, including cytoplasmic condensation,
nuclear fragmentation and membrane blebbing. These
results were confirmed by Annexin-V/PI staining analysis
(Fig. 4B): cells treated with SB202190 showed signifi-
cantly increased levels of apoptosis. Taken together, these
Inhibition of p38-MAPK impairs MDR1 expression and func- tion of P-gp in SGC7901/VCR cells Figure 3
Inhibition of p38-MAPK impairs MDR1 expression 
and function of P-gp in SGC7901/VCR cells. SGC7901/
VCR cells were treated with DMSO or SB202190 (10 μM). 
(A) Protein levels of P-gp were detected by Western-blot 
analysis. A representative example of an experiment that was 
repeated three times is shown. (B) SGC7901/VCR cells were 
treated with DMSO and SB202190. Expression of MDR1 
mRNA was assessed by RT-PCR. β-actin mRNA levels were 
measured as positive internal controls. (C) The MDR1 
mRNA expression levels were normalized to those of β-actin 
and are the means ± SD of at least three independent exper-
iments. Significant differences are indicated by asterisks. *, P 
< 0.05. (D)Effects of SB202190 on Rh123 accumulation (left) 
and retention (right) in SGC7901 and SGC7901/VCR cells. 
(left) Cells treated with SB202190 (10 μM) or vehicle control 
(0.1% DMSO). Rh123 (1 μg/mL) was added, and the cells 
were incubated for 120 min. (right) Cells were incubated 
with Rh123 for 120 min, washed, and resuspended in 
medium with SB202190 (10 μM)or vehicle control (0.1% 
DMSO) for 120 min. Rh123 fluorescence was measured 
using FAC scan. Means ± SD from three independent experi-
ments. *P < 0.05 vs SGC7901 cells. **P < 0.05 vs vehicle con-
trol.BMC Cancer 2008, 8:375 http://www.biomedcentral.com/1471-2407/8/375
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results indicate that inhibition of p38-MAPK increases the
sensitivity of SGC7901/VCR cells to chemotherapy
Discussion
Multidrug resistance (MDR) is a phenomenon by which
tumor cells develop cross-resistance to a range of structur-
ally and functionally unrelated drugs [33]. MDR is one of
the main obstacles to successful cancer therapy [34]. Many
different mechanisms have been suggested to explain the
development of a MDR phenotype in cancer cells, one of
the extensively studied form of these mechanisms is over-
expression of several energy dependent drug efflux pumps
that belong to the ATP-binding cassette family of trans-
porters, such as the P-glycoprotein (P-gp) and the MDR-
associated proteins (MRPs) [33]. P-gp is a product of the
MDR1  gene. Overexpression of MDR1  has often been
reported in primary gastric adenocarcinoma [35,36].
However, there are some reports showing that P-gp-asso-
ciated MDR cells develop other mechanisms to acquire
chemoresistance to P-gp-unrelated drugs [5-9]. In this
study, we found that constitutive overexpression of the
MDR1  gene in drug-resistant human gastric cancer
SGC7901/VCR cells is dependent on phosphorylation of
p38 and the activity of AP-1. Inhibition of p38-MAPK
could restore the sensitivity of these cells to P-gp-related
drug and P-gp-unrelated drugs
Cultured tumor cells, when selected for resistance to an
anti-neoplastic agent, often acquire cross-resistance to
others. In this study, we showed that vincristine-rsistant
SGC7901/VCR is a multidrug-resistant cancer cell line,
which was resistant to P-gp-related drug (eprubicin) and
P-gp-unrelated drugs (5-FU and cisplatin). Vincristine and
epirubicin are known substrates of P-glycoprotein, and it
is now increasingly evident that P-gp-associated MDR
cells were conferred a cross-resistance to P-gp-unrelated
drugs [8,9]. We then examined and compared the levels of
MDR1 gene expression in SGC7901/VCR and SGC7901
cells, and showed SGC7901/VCR cells have increased
expression levels of P-gp protein and MDR1 mRNA than
SGC7901. But cisplatin or 5-FU treatment could not
induce MDR1 gene expression in SGC7901 cells. Taken
together, these results suggested SGC7901/VCR cells may
develop P-gp-related or unrelated mechanism to acquire
chemoresistance. Thus, P-gp-associated MDR cell line-
SGC7901/VCR has ability to crossresist against P-gp-
related drug (eprubicin) and P-gp-unrelated drugs (5-FU
and cisplatin). Our results was in agreement with previous
findings that the P-gp-prominent MDR cell was cross-
resistant to 5-FU and cisplatin[37].
It has previously been reported that the human MDR1
promoter contains an AP-1-binding site [38], and
increased AP-1 binding [39] has been observed in several
multidrug-resistant cell lines whereas reduced AP-1 bind-
ing has been associated with increased drug sensitivity in
others [11,40]. In this study, we observed increased AP-1
activity in SGC7901/VCR cells compared with the drug-
sensitive parental SGC7901 cells. This result indicates that
increased activity of AP-1 is correlated with increased drug
resistance in SGC7901/VCR cells.
Recently, increasing evidence indicates that anticancer
drugs activate many signal pathways, some of which are
connected to the development of drug resistance of tumor
cells [41]. The MAP kinase pathway is an important sig-
nal-transduction pathway activated by many different
stimuli. Previous reports have shown that modulators of
the MAP kinase pathway can affect drug transport activity
of P-gp in certain multidrug-resistant cell lines [42,43].
We investigated the role of the MAP kinase signal pathway
in drug-resistant and drug-sensitive cell lines. As shown in
Fig. 3B and 3C, phosphorylation of p38 was increased in
SGC7901/VCR cells, but there were no differences in
phosphorylation of JNKs and ERKs between drug-resist-
ant and drug-sensitive cell lines. Meanwhile, AP-1 activity
was significant attenuated by SB202190 or after cotrans-
fection with the DN-p38 plasmid. We also observed that
inhibition of p38 by SB202190 markedly decreased levels
of P-gp, MDR1 mRNA and function of P-gp. Moreover,
the function of P-gp can also be repressed by SB202190
(Fig. 3D) in SGC7901/VCR cells. Furthermore, incubation
with cisplatin for 24 h can also induce p38 phosphoryla-
tion in SGC7901 cells; this result is supported by previous
report that p38 MAPK was preferentially activated by cis-
Inhibition of p38 MAPK increases SGC7901/VCR to chemo- therapy Figure 4
Inhibition of p38 MAPK increases SGC7901/VCR to 
chemotherapy. SGC7901/VCR cells were treated with 
indicated concentrations of cisplatin, 5-FU or epirubicin, with 
or without SB202190 (10 μM), for 24 hours. (A) The mor-
phology of cells was observed, and photographs were taken 
under the microscope. (B) Flow cytometry analysis was per-
formed after staining with Annexin V/PI. Compared with the 
control cells (without SB202190), there were significantly 
more apoptotic cells in the SB230920 treatment group. A 
representative example of an experiment that was repeated 
three times is shown.BMC Cancer 2008, 8:375 http://www.biomedcentral.com/1471-2407/8/375
Page 7 of 9
(page number not for citation purposes)
platin in several cell lines [44]. Thus, these results suggest
that the p38-MAPK/AP-1 signal pathway is involved in
regulation of the MDR1 gene in SGC7901/VCR cells, and
may contribute to chemoresistantce. Our results were in
line with previous report that the specific p38-MAPK
inhibitor SB203580 blocked both c-fos and c-jun expres-
sion in response to UV irradiation and anisomycin [45].
Although p38-MAPK does not phosphorylate or activate
c-Jun, several lines of evidence however, support the idea
that p38 can contribute to AP-1 activity. p38 can contrib-
ute to c-jun gene induction mediated by the AP-1 binding
site in the c-jun promoter. In addition to the AP-1 site, the
c-jun gene can be regulated by MEF2 family of transcrip-
tion factors (consisting of MEF2 A-D) [46]. The MEF2 site
is critical for induction of the c-jun promoter by LPS in
macrophages, and that this induction requires functional
p38 and transcription factor MEF2C. Furthermore,
MEF2C was shown to be directly phosphorylated and acti-
vated by p38 [47]. Thus, p38 can potentially regulate c-Jun
transcriptional activity by regulating transcription factors
that bind to the AP-1 site as well as the MEF2 site.
It has been previously reported in other cell lines that p38-
MAPK does not affect P-gp and MDR1 mRNA expression
[48,49]. In this study, we demonstrated that inhibition of
p38-MAPK by SB202190 significantly attenuated the
activity of AP-1 and MDR1 gene expression. As AP-1 is the
important transcription factor for MDR1 gene expression,
we suggest that SB202190 inhibited MDR1 gene expres-
sion by reducing the activity of transcription factor AP-1.
Thus, the effect of p38-MAPK on MDR1 gene expression is
cell type dependent.
Previous reports have showed that increased expression of
c-Jun  contributed to cisplatin resistance, and 5-FU can
induce  c-Jun  phosphorylation and activate AP-1-specific
transcription [31,32]. Meanwhile, we have demonstrated
that the activity of Ap-1 was upregulated in SGC7901/VCR
cells and inhibition of p38-MAPK by SB202190 can reduce
the activity of AP-1 and inhibit MDR1  gene expression.
Therefore, we investigated the effect of SB202190 on the
multidrug-resistant phenotype of drug-resistant SGC7901/
VCR cells. As shown in Fig. 6, SB202190 significantly
increased the sensitivity of drug-resistant SGC7901/VCR
cells to chemotherapeutic agents, which indicates that
SB202190 may reverse the multidrug-resistant phenotype
in SGC7901/VCR cells. Our results were consistent with
previous reports that pharmaceutical inhibition of p38 by
SB203580 reversed the multidrug resistance of L1210/VCR
cells [42]. It has also been reported that the p38 MAPK
pathways play an important role in cellular resistance
against photodynamic therapy with hypericin in HeLa cells
[50]. Therefore, it could be suggested from our results that
drug resistance in SGC7901/VCR cells is attributed at least
in part to the activation of p38-MAPK/AP-1 signal pathway,
and downregulation of this pathway appears to confer on
MDR cells sensitivity to P-gp-unrelated drugs as well as P-
gp-related drug. Several reports have showed that specific
inhibitors of signal pathway can reverse P-gp-mediated
multidrug resistance [42,43,51,52]. Thus, interrupting sig-
nal-transduction pathways that mediate the expression of
multidrug transporters might be an effective approach to
prevent multidrug resistance and increase sensitivity to
chemotherapy in human cancers. Taken together, our data
indicate that the p38-MAPK signal pathway affects MDR1
gene expression, and provide a possible new mechanism
for cross-resistance in drug-resistant human gastric cancer
cells. These results further our understanding of the regula-
tory mechanisms involved in MDR1 gene expression and
may provide new strategies for reversal of multidrug resist-
ance in human gastric cancer cells.
Conclusion
Activation of the p38-MAPK pathway might be responsi-
ble for the modulation of P-glycoprotein-mediated multi-
drug resistance in the SGC7901/VCR cell line.
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